BioXcel Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
May 26 2021 - 7:00AM
BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq:
BTAI), a clinical-stage biopharmaceutical company utilizing
artificial intelligence approaches to develop transformative
medicines in neuroscience and immuno-oncology, today announced that
Dr. Vimal Mehta, Founder and Chief Executive Officer of BioXcel,
will participate in fireside chats at three upcoming virtual
healthcare investor conferences.
Presentation Details:
Event: Jefferies Virtual Healthcare
ConferenceDate: Wednesday, June 2,
2021Time: 10:30 AM ET
Event: Goldman Sachs 42nd Annual Global
Healthcare ConferenceDate: Wednesday, June 9,
2021Time: 4:40 PM ET
Event: BofA Securities Napa Biopharma
ConferenceDate: Monday, June 14,
2021Time: 11:30 AM ET
Live webcasts of the fireside chats will be accessible through
the Investors section of the Company's website at
www.bioxceltherapeutics.com. Following the conferences, the
webcasts will be archived on the Company’s website for at least 30
days.
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical
company utilizing artificial intelligence approaches to develop
transformative medicines in neuroscience and immuno-oncology.
BioXcel’s drug re-innovation approach leverages existing approved
drugs and/or clinically validated product candidates together with
big data and proprietary machine learning algorithms to identify
new therapeutic indices. BioXcel’s two most advanced clinical
development programs are BXCL501, an investigational, proprietary,
orally dissolving thin film formulation of dexmedetomidine for the
treatment of agitation and opioid withdrawal symptoms, and BXCL701,
an investigational, orally administered, systemic innate immunity
activator in development for the treatment of aggressive forms of
prostate cancer and advanced solid tumors that are refractory or
treatment naïve to checkpoint inhibitors. For more information,
please visit www.bioxceltherapeutics.com.
Contact Information:
BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com
Investor Relations:Mary ColemanBioXcel Therapeutics, VP of
Investment RelationsMColeman@bioxceltherapeutics.com
1.475.238.6837
John GrazianoSolebury Troutjgraziano@soleburytrout.com
1.646.378.2942
Media:
Julia DeutschSolebury Troutjdeutsch@soleburytrout.com
1.646.378.2967
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Apr 2023 to Apr 2024